Comparative Pharmacology
Head-to-head clinical analysis: LEGUBETI versus TZ 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEGUBETI versus TZ 3.
LEGUBETI vs TZ-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Legubeti is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin secretion.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
500 mg orally twice daily
100 mg orally twice daily
None Documented
None Documented
Terminal half-life: 12 hours; steady-state reached after 2-3 days; adjust dose in renal impairment
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
Category C
Category C
Unknown
Unknown